A specific synbiotic-containing amino acid-based formula in dietary management of cow's milk allergy: a randomized controlled trial.
Bifidobacterium breve M-16V
Cow’s milk allergy
Gut microbiota
Prebiotic
Probiotic
Symptoms
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
08
2018
accepted:
04
01
2019
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
18
1
2019
Statut:
epublish
Résumé
Here we report follow-up data from a double-blind, randomized, controlled multicenter trial, which investigated fecal microbiota changes with a new amino acid-based formula (AAF) including synbiotics in infants with non-immunoglobulin E (IgE)-mediated cow's milk allergy (CMA). Subjects were randomized to receive test product (AAF including fructo-oligosaccharides and The trial included 35 test subjects, 36 controls, and 51 in the healthy reference group. Study product was continued by 86% and 92% of test and control subjects between week 8-12, and by 71% and 80%, respectively until week 26. At week 26 median percentages of bifidobacteria were significantly higher in test than control [47.0% vs. 11.8% ( Beneficial effects of this AAF including specific synbiotics on microbiota composition were observed over 26 weeks, and shown suitable for dietary management of infants with non-IgE-mediated CMA.
Sections du résumé
BACKGROUND
BACKGROUND
Here we report follow-up data from a double-blind, randomized, controlled multicenter trial, which investigated fecal microbiota changes with a new amino acid-based formula (AAF) including synbiotics in infants with non-immunoglobulin E (IgE)-mediated cow's milk allergy (CMA).
METHODS
METHODS
Subjects were randomized to receive test product (AAF including fructo-oligosaccharides and
RESULTS
RESULTS
The trial included 35 test subjects, 36 controls, and 51 in the healthy reference group. Study product was continued by 86% and 92% of test and control subjects between week 8-12, and by 71% and 80%, respectively until week 26. At week 26 median percentages of bifidobacteria were significantly higher in test than control [47.0% vs. 11.8% (
CONCLUSION
CONCLUSIONS
Beneficial effects of this AAF including specific synbiotics on microbiota composition were observed over 26 weeks, and shown suitable for dietary management of infants with non-IgE-mediated CMA.
Identifiants
pubmed: 30651972
doi: 10.1186/s13601-019-0241-3
pii: 241
pmc: PMC6332540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Références
Clin Exp Allergy. 1999 Nov;29(11):1502-6
pubmed: 10520078
Gut. 2000 Oct;47(4):506-13
pubmed: 10986210
J Allergy Clin Immunol. 2008 Jun;121(6):1448-54
pubmed: 18436293
J Nutr. 2008 Jun;138(6):1141-7
pubmed: 18492847
Appl Environ Microbiol. 2009 Feb;75(4):965-9
pubmed: 19088308
Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 1):67-73
pubmed: 19566584
Int Arch Allergy Immunol. 2010;151(2):107-17
pubmed: 19752564
Clin Exp Allergy. 2010 May;40(5):795-804
pubmed: 20184604
J Allergy Clin Immunol. 2011 Sep;128(3):646-52.e1-5
pubmed: 21782228
Clin Pediatr (Phila). 2012 Apr;51(4):337-44
pubmed: 22013147
J Allergy Clin Immunol. 2012 Feb;129(2):580-2, 582.e1-5
pubmed: 22078573
BMJ Open. 2012 Mar 05;2(2):e000637
pubmed: 22396223
J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):221-9
pubmed: 22569527
Nutr J. 2013 Feb 08;12:22
pubmed: 23394146
Georgian Med News. 2013 Mar;(216):39-45
pubmed: 23567307
J Pediatr. 2013 Sep;163(3):771-7.e1
pubmed: 23582142
Acta Paediatr. 2013 Oct;102(10):990-8
pubmed: 23837862
Georgian Med News. 2013 Jun;(219):46-52
pubmed: 23863210
Methods. 2014 Mar 1;66(1):22-33
pubmed: 23954566
J Pediatr Gastroenterol Nutr. 2013 Sep;57(3):281-6
pubmed: 23974059
Pediatr Res. 2014 Feb;75(2):343-51
pubmed: 24216543
Expert Rev Clin Immunol. 2014 Feb;10(2):257-67
pubmed: 24410539
Clin Exp Allergy. 2015 Jan;45(1):43-53
pubmed: 24773202
Eur Ann Allergy Clin Immunol. 2014 May;46(3):100-5
pubmed: 24853567
Pediatr Allergy Immunol. 2014 Aug;25(5):428-38
pubmed: 24899389
Mediators Inflamm. 2014;2014:249784
pubmed: 25002754
Allergol Int. 2014 Dec;63(4):575-85
pubmed: 25056226
Eur J Pediatr. 2015 Feb;174(2):141-50
pubmed: 25257836
Br J Nutr. 2015 Apr 14;113(7):1102-12
pubmed: 25781481
Iran J Pediatr. 2014 Feb;24(1):29-34
pubmed: 25793042
Pediatr Allergy Immunol. 2015 Jun;26(4):316-22
pubmed: 25845680
Allergy. 2015 Aug;70(8):963-72
pubmed: 25864712
Clin Immunol. 2015 Aug;159(2):170-6
pubmed: 25988860
Curr Pediatr Rev. 2015;11(4):293-7
pubmed: 26239112
Microbiome. 2015 Sep 24;3:41
pubmed: 26399409
ISME J. 2016 Apr;10(4):1002-14
pubmed: 26430856
Science. 2016 Apr 29;352(6285):539-44
pubmed: 27126036
Ann Clin Biochem. 2017 Mar;54(2):246-252
pubmed: 27194747
J Allergy Clin Immunol. 2016 Oct;138(4):1122-1130
pubmed: 27292825
Sci Transl Med. 2016 Jun 15;8(343):343ra81
pubmed: 27306663
Cell Rep. 2016 Jun 21;15(12):2809-24
pubmed: 27332875
PLoS One. 2016 Jun 30;11(6):e0158498
pubmed: 27362264
J Pediatr Gastroenterol Nutr. 2016 Oct;63(4):e43-53
pubmed: 27472478
Minerva Pediatr. 2016 Dec;68(6):478-486
pubmed: 27668453
Cytokine. 2016 Dec;88:259-266
pubmed: 27697703
Immun Inflamm Dis. 2016 Mar 24;4(2):155-165
pubmed: 27933160
Front Microbiol. 2017 Mar 06;8:356
pubmed: 28321211
J Cyst Fibros. 2017 Sep;16(5):631-636
pubmed: 28416415
Clin Transl Allergy. 2017 Aug 23;7:26
pubmed: 28852472
Pediatr Res. 2018 Mar;83(3):677-686
pubmed: 29155807
Lancet. 1978 Oct 7;2(8093):763-4
pubmed: 80688